PillBots, the revolutionary bite-sized piece of technology that has the potential to transform gastrointestinal health, are currently undergoing clinical trials with hopes of obtaining FDA review soon. If successful, these tiny robots could make their commercial launch as early as 2026.
Developed by Endiatx, PillBots are a swallowable robot designed to perform non-invasive endoscopies using cameras and sensors. By replacing the need for upper endoscopies (EGD), doctors can quickly examine a patient’s stomach over a telemedicine call. This “moving eyeball in the stomach” can navigate internal issues without sedation or requiring the patient to fast before the procedure.
Once ingested, the PillBot moves around the body using patented multi-pumpjet propulsion controlled remotely by doctors. It provides a live feed inside the patient’s body, illuminated by its own LED system, which can be saved for AI-enhanced analysis later on. CEO Torrey Smith has demonstrated the process by swallowing the PillBot over 40 times, and it passes through the gastrointestinal system within 24 hours.
Endiatx aims to make PillBots available for over-the-counter purchases at around $50 each with $7 million in funding. The company is also exploring PillSurgeon, a more advanced version of the PillBot that can remove polyps, collect microbiome samples, cauterize bleeds, and perform biopsies. Overall, PillBot technology shows promising potential for revolutionizing gastrointestinal health care in the future.
